TransCon CNP is a synthetic peptide commercialized by Ascendis Pharma, with a leading Phase II program in Achondroplasia. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 2 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of TransCon CNP’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for TransCon CNP is expected to reach an annual total of $152 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TransCon CNP Overview
ACP-015 (TransCon CNP) is under development for the treatment of achondroplasia. It is administered through subcutaneous route. The drug candidate is a long-acting prodrug of the C-type natriuretic peptide conjugated to a multi-arm polyethene glycol carrier molecule through a cleavable linker. The drug candidate acts by targeting fibroblast-growth-factor-receptor 3 (FGFR3). It is developed based on the transcon technology.
Ascendis Pharma Overview
Ascendis Pharma is a biopharmaceutical company that focuses on developing drugs for endocrinology and oncology indications. It is investigating TransCon hGH, a long-acting human growth hormone prodrug targeting GHD (growth hormone deficiency); TransCon PTH drug to treat hypoparathyroidism by restoring physiologic levels of PTH (parathyroid hormone); and TransCon CNP, a CNP (C-type natriuretic peptide) drug against achondroplasia (ACH). It is also evaluating TransCon TLR (toll-like receptor) 7/8 agonist, and TransCon IL-2 β/γ, an interleukin-2 variant that activates the IL-2 receptor beta/gamma (IL-2Rβ/γ) for the treatment of cancer. Ascendis Pharma utilizes its proprietary TransCon technology platform to develop its drugs. The company has its operations in the US, Germany and Denmark. Ascendis Pharma is headquartered in Copenhagen, Denmark.
The company reported revenues of (Euro) EUR51.2 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of EUR7.8 million in FY2021. The operating loss of the company was EUR561.8 million in FY2022, compared to an operating loss of EUR451.8 million in FY2021. The net loss of the company was EUR583.2 million in FY2022, compared to a net loss of EUR383.6 million in FY2021.
For a complete picture of TransCon CNP’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.